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Abstract
The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with
intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant
cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have
been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized
clinical trials, as well as by critical evaluation of criteria for progression. However, these reports have not penetrated
the community, and many patients do not receive appropriate therapy. Additionally, several immune checkpoint
inhibitors have recently been approved for treatment of metastatic disease. The approval of immune checkpoint
blockade for patients with platinum-resistant or -ineligible metastatic bladder cancer has led to considerations of
expanded use for both advanced and, potentially, localized disease. To address these issues and others surrounding
the appropriate use of immunotherapy for the treatment of bladder cancer, the Society for Immunotherapy of Cancer
(SITC) convened a Task Force of experts, including physicians, patient advocates, and nurses, to address issues related
to patient selection, toxicity management, clinical endpoints, as well as the combination and sequencing of therapies.
Following the standard approach established by the Society for other cancers, a systematic literature review and analysis
of data, combined with consensus voting was used to generate guidelines. Here, we provide a consensus statement for
the use of immunotherapy in patients with bladder cancer, with plans to update these recommendations as the field
progresses.
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Background
Despite a slight but steady decrease in incidence and
deaths from bladder cancer over the past few decades in
the U.S., an estimated 79,000 people will be newly diag-
nosed in 2017, and nearly 17,000 will die from the disease
[1]. These data underscore the need for novel treatment
strategies to improve patient outcomes. As understanding
of the role of the immune system in the pathogenesis of
cancer has advanced, there has been increasing interest in
treatments that rely on immunomodulatory mechanisms
to target and destroy cancer cells. Such agents, which in-
clude cytokines, monoclonocal antibodies, immune check-
point inhibitors, T cell therapies, oncolytic viruses and
vaccines, have allowed a subset of patients to benefit from
durable response rates, often with a more tolerable ad-
verse event profile than traditional therapies [2]. The need
to identify why certain patients respond to a given therapy
when others fail to achieve measurable clinical benefit has
led to energetic efforts to identify and validate predictive
biomarkers that can guide patient selection, and prognos-
tic biomarkers to help evaluate likely disease outcomes.
Other key areas of interest include rational combination
therapies and drug sequencing, and the potential role of
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systemic immunotherapy to treat organ-confined and
early disease.T1
Given the immunological nature of the standard treat-
ment approach to bladder cancer, which relies on intra-
vesical instillation of Bacillus Calmette-Guérin (BCG), a
live, attenuated strain of Mycobacterium bovis, there is a
clear rationale for expanded use of immune-based treat-
ments for bladder cancer. In order to enable clinicians
to understand and use the increasing number of emer-
ging immunotherapies effectively and safely, the Society
for Immunotherapy of Cancer (SITC) convened a Task
Force of experts on bladder cancer, including physicians,
patient advocates, and nurses, to address issues related
to patient selection, toxicity management, clinical end-
points, and sequencing and combination of therapies.
This panel met initially in December 2014 with the goal of
generating consensus recommendations for the clinical
use of immunotherapy for bladder cancer. Discussion at
this meeting centered on the various consensus papers re-
cently published, and how these might be refined, or vari-
ations better explained [3].
The following objectives were deemed priorities for Task
Force discussion: 1) To determine consensus on a) the
definition of risk categories and b) identification of patients
for whom intravesical immunotherapy is appropriate, 2) to
determine consensus around duration of intravesical ther-
apy and maintenance vs. non-maintenance regimens, 3) to
determine which patients this approach is not appropriate
for (i.e., patients with very low risk of progression or recur-
rence), 4) to define the timing of additional trans-urethral
resection in conjunction with BCG therapy and procedures
to reduce toxicity without impacting efficacy, and 5) to de-
fine the role of immune checkpoint blockade for metastatic
disease. Following the in-person meeting, the Task Force
continued to address recent advances in the field through
telephone and email communications. A commentary
section is provided that addresses some of these issues.
Non-muscle invasive bladder cancer (NMIBC)
NMIBC (previously commonly referred to as “superfi-
cial” bladder cancer) is the most common presentation
of urothelial cancer [4]. The treatment of NMIBC, which
depends on risk stratification based on clinical and
pathologic criteria, largely relies on transurethral resection
followed by intravesical instillation of therapy, primarily
with BCG immunotherapy [5, 6] or chemotherapy. BCG
Table 1 Ongoing Selected Immunotherapy Trials in Bladder Cancer
Completed
Drug/Agent Study Stage of Disease
Atezolizumab (MPDL3280A)
Anti-PD-L1
Cohort 1 NCT02951767, Cohort 2:
NCT02108652
Phase II Locally advanced or metastatic – progressed
after platinum-based treatment (Rosenberg
et al. Lancet 2016; Balar et al. Lancet 2016 [63, 74])
Pembrolizumab
NCT02256436
Phase III vs. standard of care chemotherapy Locally advanced or metastatic – progressed
after platinum-based treatment
Ongoing
Drug/Agent Study Stage of Disease
Durvalumab with or without
tremelimumab
NCT02516241
Phase II vs. standard of care chemotherapy Stage IV transitional cell carcinoma of the urothelium
Atezolizumab
NCT02662309
Phase II preoperative MPDL3280A Transitional cell carcinoma of the bladder
Atezolizumab combination with
cisplatin and gemcitabine
NCT02989584
Pilot safety, single-arm phase II study Metastatic bladder cancer
Atezolizumab
NCT02450331
Randomized phase III atezolizumab as adjuvant
therapy vs. observation
PD-L1 positive, high risk muscle invasive
bladder cancer
Nivolumab
NCT02632409
Randomized phase III nivolumab as adjuvant
therapy vs. placebo
High risk muscle-invasive bladder cancer
Maintenance avelumab
NCT02603432
Phase III vs. best supportive care alone Locally advanced or metastatic bladder cancer
that did not progress after completion of first-line
platinum containing chemotherapy
Pembrolizumab
NCT02335424
Phase II Non-cisplatin eligible patients
MEDI-4736 (anti-PD-L1) +/−
tremelimumab (anti-CTLA-4) NCT02516241
Phase III, three arms: MEDI-4736 +/−
tremelimumab vs. standard of care chemotherapy
Unresectable stage IV bladder cancer
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is currently the treatment of choice for urothelial carcin-
oma in situ (CIS), since it has been shown to reduce risk
of recurrence, and of progression of NMIBC after trans-
urethral resection [7]. Although the mechanisms that
underpin the efficacy of intravesical BCG are incompletely
understood, it is widely believed that immune infiltration
is essential to an effective response [8] and that both
urothelial cells and bladder cancer cells contribute to the
overall antitumor effect [9]. Several consensus panels and
guidelines have been developed in the past few years to
identify and categorize the appropriate patients to
undergo intravesical therapy [10–16]. Characteristics used
for prognostication and to guide treatment include histo-
logic grade, number of tumors, prior recurrence patterns,
extent of disease, and, if present, carcinoma in situ. Guide-
lines to date, while similar, have areas of controversy,
which imply a need to further define prognostic criteria
and optimal management, particularly with respect to
intermediate risk patients [17, 18].
Muscle invasive and advanced bladder cancer
Two randomized clinical trials as well as meta-analyses
demonstrate a survival benefit with the integration of neo-
adjuvant cisplatin-based chemotherapy prior to cystec-
tomy for patients with muscle-invasive disease. Adjuvant
cisplatin-based chemotherapy has never been definitively
proven to improve overall survival, but it is frequently
used. Systemic therapy for metastatic disease has historic-
ally consisted of platinum-based chemotherapy, and this is
discussed in the consensus report [19, 20]. The following
objectives were deemed as priorities for the discussion of
the panel meeting for muscle invasive and advanced dis-
ease: 1) to define the role of immune checkpoint inhibi-
tors in the treatment of metastatic urothelial cancer, 2) to
comment on the clinical utility of biomarkers predictive of
benefit to treatment with these therapies, and 3) to discuss
potential utility of immune-based therapy in the muscle
invasive, non-metastatic setting.
Methods
Consensus statement policy
This consensus statement utilized the National Academy
of Medicine’s (NAM, formerly the Institute of Medicine)
Standards for Developing Trustworthy Clinical Practice
Guidelines reported in March 2011 [21]. In addition, the
previously released SITC consensus guidelines were used
as a model to develop and organize this manuscript as
previously described [22, 23]. As outlined by the NAM,
the development of clinical practice guidelines should
include a transparent process. This includes information
regarding the development of guidelines, funding
sources, and the reporting and management of conflicts
of interest. Moreover, the Task Force nominated to de-
velop guidelines should be a multi-disciplinary group
and base their recommendations on evidence in the lit-
erature with a rating system to evaluate the strength of
supporting peer-reviewed literature and results from
clinical trials reported.
To develop these guidelines, SITC sponsored a panel
led by a steering committee of bladder cancer experts who
met in December 2014 in person. To discuss updates to
the field, the panel subsequently communicated via email.
The meeting and follow-up discussions were guided with
the goal of developing clinical treatment guidelines specif-
ically for immunotherapy in bladder cancer patients. This
consensus statement is only intended to provide guidance;
it is not to be used as a substitute for the individual
professional judgment of the treating physician. The full
version of this consensus report and others can be found
on the SITC website [23]. Because of differences in drug
approval, availability, and regulations in other countries,
the panel focused on drugs currently approved by the U.S.
Food and Drug Administration (FDA) for the treatment of
patients in the U.S.
Consensus panel and conflicts of interest
In accordance with the practices utilized in previous SITC
consensus guidelines, panel members were both SITC
members or nonmembers but represented multiple disci-
plines, including patient representatives, nurses, and
others expected to be affected by the development of clin-
ical practice guidelines. All Task Force members were re-
quired to disclose any conflicts of interest using the SITC
disclosure form, which requires full financial and other
disclosures concerning relationship with commercial en-
tities that could be expected to have direct regulatory or
commercial impact resulting from the publication of this
statement. An advanced copy of this manuscript was avail-
able for comment by SITC membership prior to publica-
tion (Additional file 1). No commercial funding was
provided to support the consensus panel, literature review,
or the preparation of this manuscript.
Bladder cancer consensus task force
The Task Force consisted of 17 participants, including 8
medical oncologists, 7 urologists, 1 nurse, and 1 patient
representative (Additional file 2). The urologists were
chosen for their experience in the development and
evaluation of best practice guidelines for the use and
optimization of BCG therapy, and all members were
experts in the management of the spectrum of urothe-
lial cancer. The medical oncologists were experienced
in the management of advanced bladder cancer with
both chemotherapy and immunological therapy, in-
cluding participation in clinical trials of immune
checkpoint inhibitors. Additional participants were ex-
perts in addressing issues of barriers in access to ap-
propriate use of immunotherapy. A list of the Task
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Force pre-meeting survey questions and responses is
available in Additional file 3.
Literature review
The MEDLINE database was used to perform the litera-
ture search by combining the terms “transitional cell
carcinoma OR bladder cancer OR urothelial cancer”
AND “BCG,” “interferon” “ipilimumab.” The search was
limited to clinical trials, meta-analyses, practice guide-
lines, and research in humans. The original search lead-
ing up to the meeting encompassed articles published
2006–2014 (conducted on November 21, 2014). The
literature search was updated on June 12th, 2017 to in-
clude more recent publications from the original search
and to add terms reflecting recent advances in the field.
The updated bibliography was generated by re-running
the original search for years 2015–2017, and supplement-
ing this with search results for “transitional cell carcinoma
OR bladder cancer OR urothelial cancer” in combination
with “nivolumab”, “pembrolizumab”, “atezolizumab”, “dur-
valumab”, “avelumab”, “PD-1 or PD-L1”, “combination
therapy” and “peptide-derived vaccine”. Date limits for this
aspect of the search were 2010–2017. After removing du-
plicates, reviewing the references for accuracy, and supple-
menting with additional references as identified by the
consensus panel, the updated bibliography resulted in a
213-item list (Additional file 4). Using the previously
established grading system, the supporting literature was
graded into three levels [22]. To summarize, Level A was
defined as strong, evidence-based data derived from pro-
spective, randomized clinical trials and meta-analyses.
Level B literature consisted of moderately supported data
from uncontrolled, prospective clinical trials. Level C rep-
resented weak supporting data derived from reviews and
case reports.
Consensus recomendations
What is the role of BCG therapy in non-muscle invasive
bladder cancer (NMIBC)? Specifically, when should intra-
vesical immunotherapy be used among the various risk
categories of NMIBC?
The literature and multiple consensus statements re-
port slightly different recommendations for manage-
ment of different risk categories of bladder cancer.
However, all agree that risk-stratification is key to
treatment recommendations. Additionally, the consen-
sus reports all describe significant benefit that can be
experienced by reduction in recurrence and progres-
sion. This is also stated in guidelines by the American
Urologic Association (AUA), the European Associ-
ation of Urology (EAU), and the International Bladder
Cancer Group (IBCG) [10–16].
Is there a role for BCG in high risk (high grade) bladder
cancer?
Literature review and analysis
High risk NMIBC is defined in most consensus reports
as histologically confirmed high grade tumor (including
Ta and T1 tumors) as well as carcinoma in situ [24].
High risk could also include certain large volume low
grade tumors, although most experts now would con-
sider these as intermediate risk tumors. Consensus
statements from several urologic and bladder cancer
groups (AUA, EUA, IBCG, NCCN, ICUD) recommend
induction BCG for all high risk tumors, with differing
recommendations for maintenance BCG [10–16].
BCG induction (6 weeks treatment) followed by
3 week maintenance BCG has significant beneficial
impact on disease recurrence, progression, and out-
comes, with superior results relative to chemotherapy
[25]. Several randomized trials have demonstrated this
and are summarized in Kamat et al. [14]. The final re-
port from the study EORTC 98013, in which the dose
(administered at three weekly instillations at months
3, 6, 12, 18, 24, 30, and 36 according to the SWOG
schedule) and duration (1 year versus 3 years) of BCG
maintenance were tested, demonstrated that full-dose
BCG maintenance is more effective without added
toxicities than the one-third dose at the same sched-
ule. In addition, patients with high risk disease bene-
fited from 3 years of maintenance [26]. A recently
completed Spanish Oncology Group (CUETO) study,
in which the BCG maintenance therapy was modified
to one instillation every 3 months, did not show a
benefit of maintenance [27], and this has also been
seen in a number of reports utilizing modified ap-
proaches to maintenance BCG [14]. Additionally,
EORTC conducted a trial comparing BCG mainten-
ance (SWOG schedule) to epirubicin maintenance and
demonstrated significant superiority of BCG compared
with epirubicin for all clinical parameters (time to first
recurrence, time to distant metastases, and disease-
specific as well as overall survival) in patients with
both high and intermediate risk disease [28].
A recently published European phase III trial compared
chemohyperthermia using mitomycin C (MMC) versus
BCG as adjuvant therapy for intermediate and high risk
patients [29]. Patients were accrued over 10 years, but
there were still small patient numbers (n = 190). Thus, the
study was closed early and was underpowered. However,
the results have piqued interest, in that those who were
treated per protocol had a significantly improved 24 month
recurrence-free survival following chemohyperthermia
compared with BCG alone (p = 0.02). However, there was
no significant difference if analyzed by intent to treat
(p = 0.08), and 3 week maintenance BCG was given for
only one year rather than the recommended 3 years [29].
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Consensus recommendations
Based on guidelines reflecting results of randomized
clinical trials, the Task Force unanimously recommended
that BCG therapy for high risk patients should be con-
sidered standard of care for this patient category (Fig. 1).
However, the definition of high risk patient subgroups
continues to be refined. Although maintenance BCG will
be discussed below, it appears to be critical for success-
ful management of high risk patients. In addition, the
SWOG schedule is reproducibly providing the best efficacy.
This recommendation is based on Level A evidence from
randomized studies over several years [10–16, 25, 26].
What is the role of BCG in carcinoma in situ of the
bladder?
Literature review and analysis
Carcinoma in situ is considered high risk disease and, in
most guidelines, the recommendation is for treatment
with BCG, including both induction and maintenance
based on randomized trials [10–15, 17, 18]. However,
some would recommend the use of intravesical
chemotherapy first and BCG at recurrence. One study
that forms the basis of this approach reported long-term
results of a randomized trial with a subset of 68 patients
with carcinoma in situ [30]. The treatment consisted of
mitomycin induction followed by maintenance of
monthly alternating instillations of mitomycin and BCG
versus mitomycin alone for up to 2 years [30]. No sig-
nificant difference was found between the two groups,
but the non-stratified risk of dying from bladder cancer
was low overall at 28% at 15 years, with a follow-up of
living patients of 17 years [30]. The EORTC study
30,993 was a randomized phase II trial of 96 patients
with carcinoma in situ, comparing sequential mitomycin
and BCG with BCG alone [31]. The endpoints included
complete response at first cystoscopy 16–18 weeks after
start of treatment, as well as disease-free and overall sur-
vival. Complete responders received maintenance on
their treatment arm every 3 months for up to 3 years.
The complete response and disease-free rates were simi-
lar in both groups [31]. Another approach that has been
reported, but not widely adopted, is sequential BCG
Fig. 1 Treatment algorithm for non-muscle invasive bladder cancer. All of the treatment options shown may be appropriate. The selection of
therapy should be individualized based on patient eligibility and the availability of the therapy at the discretion of the treating physician. These
algorithms are meant to provide advice as the consensus recommendations of the Task Force. (1) The Task Force defines Low Risk as solitary,
primary low-grade Ta tumor. (2) Intermediate Risk is defined as histologically-confirmed multiple and/or recurrent low-grade Ta tumors. (3) High
risk is defined as any T1, high-grade and/or carcinoma in situ
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followed by electromotive mitomycin, particularly for
high risk patients and carcinoma in situ [32]. Although
sequential treatment of BCG and electromotive mitomy-
cin C did show efficacy, challenges with its tolerability
were reported [32].
Consensus recommendations
BCG immunotherapy is recommended in most guidelines
for carcinoma in situ of the bladder, as it is a high risk cat-
egory, and this was also the recommendation by the Task
Force. Induction therapy with mitomycin was also dis-
cussed as an alternative to BCG. The Task Force recom-
mendations in order of preference were as follows: BCG
induction and maintenance for 3 years as per SWOG
schedule, combination of BCG and mitomycin, and trial
of mitomycin first with BCG reserved for those who fail
chemotherapy. The Task Force also recognizes that a large
majority of patients with carcinoma in situ present with
papillary tumors as well, and therefore, recognizes that the
majority of patients will end up being treated with induc-
tion and maintenance BCG primarily, rather than primary
chemotherapy.
What is the role of BCG in intermediate risk bladder
cancer?
Literature review and analysis
The IBCG has recently defined intermediate-risk disease as
multiple or recurrent low-grade Ta tumors and provided
guidance on further stratifying these patients into categories
of lower versus higher risk of recurrence or progression
based on key factors, including histologic grade, centricity
of tumors, size of tumors, and rate of recurrence following
resection [17]. The IBCG proposes that the following fac-
tors be considered to aid in clinical decisions in intermedi-
ate risk disease: number (>1) and size of tumors (> 3 cm),
timing (recurrence within 1 year), frequency of recurrences
(> 1 per year), and previous treatment. In patients without
these risk factors, a single, immediate instillation of chemo-
therapy is advised. In those with 1–2 risk factors, induction
BCG with maintenance or additional intravesical chemo-
therapy are recommended, and previous intravesical ther-
apy should be considered when choosing between these
therapies. For those with 3–4 risk factors, induction plus
maintenance BCG is recommended [17]. Treatment rec-
ommendations reflect the spectrum of the disease and do
vary among groups [10–18]. Based on early results of
EORTC 30911 in 500 intermediate risk patients, BCG in-
duction with 3-week maintenance utilizing the SWOG
schedule, had significant beneficial impact on disease recur-
rence, progression, and outcomes [14, 28]. Similarly, inter-
mediate risk patients were included in EORTC 98013 and
demonstrated benefit similar to the high risk patients. How-
ever, it was recommend to treat these patients at full dose
for 1 year rather than for 3 years [27]. Again, the recent
publication reporting chemohyperthermia should also be
taken into consideration [29].
Consensus recommendations
The Task Force discussed risk stratification at length and
agreed that there were varying definitions of intermediate
risk. However, most felt that that most of these patients
(other than those with none of the aforementioned risk
factors) would benefit from BCG based on Level A evi-
dence from randomized clinical trials. The Task Force
unanimously advocated for risk stratification as a basis for
deciding therapy and recommend that the risk category
for the tumors be carefully assessed and the transition
from low risk to intermediate risk be carefully defined.
The EORTC 30911 study comparing 3-week maintenance
BCG and epirubicin chemotherapy found that intermedi-
ate risk patients had even a greater reduction in metastasis
and mortality than high risk patients [28]. Thus, the Task
Force recommends that BCG induction and at least 1 year
of maintenance therapy be used for patients with inter-
mediate risk tumors.
Is there a role of BCG in low risk bladder cancer?
Literature review and analysis
Low grade NMIBC that occur for the first time are con-
sidered low risk NMIBC. Although patients with low
risk NMIBC have been shown in randomized studies to
benefit from BCG in terms of risk reduction [16], its use
must be weighed against the potential for side effects. In
general, consensus guidelines do not recommend the
use of BCG for these low risk tumors (i.e., small, solitary,
superficial low-grade tumors [Ta]) [4–10]. The EAU and
the AUA suggest consideration of the use of BCG when
low grade tumors are large, multifocal, and/or recurrent
(i.e., when these tumors fall into the intermediate risk
category [Fig. 1]) [10–16]. It has been noted that BCG
can be less effective in low grade tumors, presumably
because they are less antigenic [33].
Consensus recommendations
The Task Force unanimously recommended that low risk
patients (solitary, first time with low grade tumors)
should not receive BCG (Fig. 1).
What is the role of maintenance BCG?
Literature review and analysis
All guidelines recommend induction and maintenance
BCG of 1–3 years for high risk patients with a risk
reduction in terms of recurrence [10–18]. However, the
ICUD guidelines only include maintenance BCG for
carcinoma in situ, not for Ta high grade tumors [14]. This
differs from the recommendations of AUA, EUA, and
IBCG. As reviewed in previous sections, BCG induction
and maintenance has been shown to be beneficial in
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patients with high risk and intermediate risk groups utiliz-
ing the SWOG schedule [14, 24–28]. Modifications in
terms of reduction in dose or in the number of doses per
session of maintenance have not been shown as beneficial
[14, 27, 28]. Again, an improved definition of the patient
subgroups who would benefit continues to be a topic of
active clinical research. The report of EORTC 98013 sug-
gests that 1 year of maintenance utilizing the SWOG
schedule is sufficient for intermediate risk patients [27].
However, recurrence directly correlated with the duration
of maintenance, with 3-year maintenance resulting in
fewer recurrences in each dose group.
Consensus recommendations
The members of the Task Force had different opinions
on this issue. However, it was agreed upon that all high
risk (high grade) patients should receive maintenance
therapy for 3 years, while intermediate risk patients
should receive maintenance therapy for at least 1 year
based on Level A evidence.
What is the optimal timing and schedule of post-
resection immunotherapy for NMIBC?
Literature review and analysis
Most guidelines recommend intravesical immunotherapy
be initiated after an interval of at least two weeks follow-
ing transurethral resection or biopsy of the bladder to
avoid systemic absorption [10–16], unless repeat resection
is to be performed (at 4–6 weeks as recommended for all
high grade T1 patients and selected high grade Ta patients
[per EAU guidelines]). Unlike chemotherapy, BCG should
never be administered within 24 h of bladder tumor resec-
tion and can in fact be dangerous. Non-randomized stud-
ies show no advantage of early administration. There are
no randomized data suggesting an optimal time to first
dose (2 to 4 weeks). Additionally, patients who tolerate
6 weeks of BCG induction and are at high risk for tumor
recurrence and progression should be treated with main-
tenance BCG using the SWOG schedule: 3 weekly instilla-
tions at 3, 6, 12, 18, 24, 30, and 36 months [10–16, 25].
Consensus recommendations
The Task Force agreed with the recommendation to wait
at least 2 weeks before instillation of BCG after resection
of tumor(s) based on Level A evidence. In addition, the
Task Force agrees with the 6 + 3 schedule (also known
as the ‘Lamm’ or ‘SWOG’ schedule) of maintenance
BCG administration based on Level A Evidence.
What is the recommended initial and maintenance dose
of BCG?
Literature review and analysis
Based on clinical trials and clinical experience, the initial
course should be 1 vial of BCG (TICE® is 50 mg; Theracys®
is 81 mg) usually containing approximately 5 × 108 or
more CFU (the amount present in vials approved for
intravesical instillation) weekly for 6 weeks [25]. This is
accepted by the AUA, EUA, and the IBCG [10–16].
Increasing side effects may be reduced by serial re-
ductions in BCG dose; most recommended dose re-
ductions are at one-third, one-tenth, one-thirtieth,
and one-one hundredth [26]. Randomized clinical tri-
als have reported conflicting results regarding the effi-
cacy and improved safety of dose reduction. The
highly cited randomized trial by Oddens et al. showed
efficacy in the following order: full dose for 3 years,
one-third dose for 3 years, full dose for one year, and
lastly one-third dose for one year [26].
Consensus recommendations
The Task Force recommended full doses for induction
and the dose reduction during maintenance if necessary
based on side effects, which is based on Level A
evidence. The Task Force did concede that during times
of BCG shortage, as has happened in recent times, it is
acceptable to start induction with one-third dose if this
allows a vial of BCG to be split among 3 patients to
allow more patients to receive BCG than if this were not
done.
What are contraindications to the administration of BCG?
Literature review and analysis
Instillation of BCG in the presence of gross hematuria can
result in systemic absorption and toxicity from BCG. Thus,
BCG should not be instilled in the presence of gross
hematuria or active urinary infection. Treatment of on-
going urinary tract infections prior to BCG instillation may
reduce toxicity. In a study in which patients with high-risk
NMIBC received induction intravesical BCG, 61/243 had
significant bacteriuria in voided urine prior to starting ther-
apy. In this study, asymptomatic bacteriuria did not appear
to increase side effects or risk of BCG toxicity and had no
impact on recurrence rates in infected patients [34].
Although BCG has been cited as contraindicated for im-
munologically compromised patients with bladder cancer,
a retrospective study reported on 45 immunosuppressed
high risk NMIBC patients treated with intravesical BCG.
Of these patients, 12 had functioning organ transplants, 23
were undergoing chemotherapy for unrelated cancers, and
10 were taking steroids for autoimmune or related diseases.
Although this study was conducted in a small patient
population, these results suggest that BCG can be safely
administered to select patients who are immunosup-
pressed. However, efficacy may be limited, as individuals
receiving immunosuppression following organ transplant-
ation were less likely to respond [35].
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Consensus recommendations
Although BCG should not be administered in the pres-
ence of active infection or gross hematuria, the Task
Force agreed that asymptomatic bacteriuria did not ap-
pear to increase toxicities or risk thereof based on Level
B evidence. In addition, BCG appears to be safe and
effective in select patients who are immunosuppressed
based on small cohort studies (Level C evidence).
What is the value of using oral quinolones following BCG
administration?
Literature review and analysis
Administration of oral quinolones can reduce toxicity
from BCG therapy and should be routinely considered in
all patients undergoing intravesical BCG therapy. These
data are based on two randomized clinical trials, illustrat-
ing that instillation can result in up to 20% reduction in
side effects from BCG therapy [36, 37]. It is important to
note that quinolones should not be administered prior to
or within 6 h of BCG instillation, as the antibiotic can kill
the BCG bacteria and abrogate efficacy [38].
Consensus recommendations
The Task Force agreed that oral quinolones (not admin-
istered prior to or within 6 h of administering BCG) can
reduce toxicity and can be considered for all patients re-
ceiving BCG based on Level A evidence.
What is the role of combination intravesical therapy with
interferon-alpha plus BCG?
Literature review and analysis
Multiple clinical trials and a meta-analysis have produced
conflicting results regarding the success of treatments
using BCG with intravesical interferon-alpha versus BCG
alone [10–16, 39, 40]. Interferon-alpha has been combined
with BCG in several studies and the role of this combin-
ation continues to be evaluated. Randomized data among
BCG naïve patients suggest similar efficacy of BCG with
or without interferon-alpha added [41]. Other reports of
the combination are in patients who have recurred after
BCG. Some of these results suggest subsequent benefit,
but others describe “BCG failure” as a poor prognostic
factor for the combination, especially among those
deemed truly “BCG unresponsive” [42–44].
Consensus recommendations
The Task Force agreed that combination approaches of
BCG plus interferon overall seemed generally no more
successful than BCG alone based on Level B evidence.
What are the evaluation criteria following BCG therapy?
Literature review and analysis
Prospective trials consistently demonstrate that the timing
of recurrence relative to BCG treatments as well as the
number of prior courses influences the risk of progression
and subsequent response to additional BCG or other
treatments. Definitions of failure patterns have been pub-
lished over the years and are reviewed by the IBCG [24].
Recent discussion regarding the failure pattern have been
put forth by Lightfoot et al. [45] and by Kamat et al. for
the IBCG, particularly for evaluation in the setting of clin-
ical trials [24]. These include the following:
1. BCG refractory: persistent high-grade disease at
6 months despite adequate BCG treatment. Adequate
BCG therapy has been administered when a patient
has received at least 5 of 6 doses of induction therapy
and at least 1 maintenance (2 of 3 doses) or 1 repeat
course (5 of 6 doses). This category also includes any
stage/grade progression by 3 months after the first
cycle of BCG (i.e., T1 high-grade disease at 3 months).
2. BCG relapsing: recurrence of high-grade disease
after achieving a disease-free state at 6 months fol-
lowing adequate BCG (as defined above). For the
purpose of being included in the BCG unresponsive
category (see below), patients should be within
6–9 months of the last BCG exposure (e.g.,
patient on maintenance therapy).
3. BCG unresponsive: includes ‘BCG refractory’ and
‘BCG relapsing’ (within 6–9 months of last BCG
exposure) patients noted above. This group
represents patients for whom further BCG is NOT
indicated and radical cystectomy is a true option.
Thus, these patients could be considered for single-
arm studies, in which they are guaranteed to receive
an experimental therapy.
4. BCG resistant (this term is not currently used but is
included here for clarity): recurrent or persistent
disease 3 months after an induction cycle. In these
cases, BCG resistance has resolved 6 months after BCG
re-treatment, with or without transurethral resection.
Other recommendations regarding patient evaluation
include:
1. Patients who have recurrent disease after adequate
BCG should have evaluation of upper tracts and
prostatic urethra [46].
2. Patients with increasing disease (number, size, grade,
or stage of disease) at the initial 3 month cystoscopic
examination should be considered unresponsive to
BCG and alternate treatment should be recommended.
Level of evidence: B
3. Patients with residual or recurrent carcinoma in situ
at the 3 month cystoscopy may benefit from 3
additional weekly BCG treatments, but those with
disease at 6 months should be considered
unresponsive to BCG.
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Level of evidence: B
Consensus recommendations
The BCG failure pattern (resistant, refractory, or relapsing)
should be considered in making decisions about further
therapy.
Which factors predict response to BCG, and how should
response to BCG be monitored?
Literature review and analysis
Multiple studies have illustrated that clinical parameters
are the strongest predictors of response to intravesical
immunotherapy with BCG [10–16]. These parameters
include grade, stage, presence of carcinoma in situ, age,
and pattern of prior BCG failure. Cystoscopy with cy-
tology at periodic intervals remains the only reliable
method to monitor response to BCG [10–16]. However,
fluorescence in situ hybridization (FISH) techniques that
detect aneuploidy of certain chromosomes in cells
voided from the bladder characterizing them as malig-
nant [47] can be used to detect so called molecular
recurrence and has been used to risk stratify patients
undergoing BCG therapy based on FISH results at early
time points [45, 46]. Notably, reflex use of FISH in the
setting of suspicious cytology has not yet been shown to
modify surveillance strategies [48].
In addition, several groups have developed risk models
based on clinical features to help predict response to
BCG [49–51], and another recent report evaluated these
models and guidelines in patients treated with intravesi-
cal chemotherapy [52]. Additional immunologic based
assays are being developed, such as the CyPRIT assay,
which is a nomogram constructed using urinary levels of
cytokines induced by BCG and predicted the likelihood
of recurrence with 85.5% accuracy (95% confidence
interval: 77.9–93.1%) [53].
Consensus recommendations
The Task Force agreed that clinical parameters (grade,
stage, and presence of carcinoma in situ) are the stron-
gest predictors of response to intravesical immunother-
apy with BCG. While Level B evidence illustrates that
urinary FISH monitoring is predictive of response to
BCG, the Task Force believes that this remains investiga-
tional and should be correlated with clinical evaluation.
How can patient support during the management of
NMIBC enhance access to appropriate management?
Literature review and analysis
Approximately 50% of patients with newly diagnosed
NMIBC do not receive appropriate therapy with intrave-
sical BCG. Reasons for this are myriad, including reluc-
tance on the part of the patient and the physician, lack
of appreciation of the potential benefit, and access to
appropriate facilities that can administer BCG. Patient
navigation approaches, or support programs developed
to help guide patients through the care system, appear
to greatly improve the latter, providing timely access to
appropriate care [54–56]. Additionally, the Urologic Dis-
eases in America Project has documented the underuse
of guideline-recommended care in NMIBC as well as in
invasive disease [57–59]. It is proposed that implement-
ing patient navigation programs may reduce the time
from diagnosis to treatment of NMIBC and could in-
crease the likelihood of actually undergoing intravesical
therapy in eligible survivors. Additionally guideline-
appropriate care is likely to improve outcomes for most
categories of early bladder cancer. This proposal is
extrapolated from a large meta-analysis of patients with
abnormal breast, cervical, colorectal, or prostate cancer
screening outcomes and the role of patient navigators to
facilitate timely cancer care [55].
Consensus recommendations
Patient navigation can eliminate barriers to oncologic
care, enhance patient decision-making, and improve the
patient experience during their cancer care, which his
has been demonstrated in screening outcomes for a var-
iety of malignancies. Bladder cancer-specific outcome
measures should be developed, validated, and utilized as
targets for patient navigation. A formal study of the effi-
cacy of these tools in patients with bladder cancer
should be undertaken, particularly given the low rate of
compliance with established treatment guidelines.
What are the most important practical aspects of
administration of BCG?
Practical issues
Literature review and analysis The use of lidocaine or
excessive lubricants during catheterization has been shown
to have inhibitory effects on BCG viability. One study in
particular, reported significant impairment of BCG viabil-
ity, dependent on dosage and time of co-incubation, with
all lubricants analyzed [60]. Several components of these
lubricants, namely lidocaine hydrochloride, glyceryl stear-
ate, propyl-4-hydroxy-benzoate and chlorhexidine diglu-
conate, were identified as responsible for this inhibition.
Moreover, the fluid recovered from the bladder after lubri-
cant assisted catheterization also showed an inhibitory
effect.
Consensus recommendations The use of lidocaine or
use of excessive lubricants is not recommended with the
administration of intravesical BCG. Additionally, with the
use of local anesthetic, patients may not be able to feel/re-
port a potentially traumatic catheterization. When
considering other practical issues for BCG administration,
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the Task Force determined that it is not necessary to rotate
patients every 15 min post BCG instillation [38]. Moreover,
patients should also be provided with a template that they
can use to record BCG treatment/cystoscopy dates (Fig. 2).
Patients should bring and complete these with each subse-
quent visit to the same or other providers.
Muscle-invasive and metastatic disease
What is the current role of immune checkpoint blockade in
metastatic urothelial carcinoma?
Literature review and analysis Multiple clinical trials
have been undertaken to evaluate the role of immune
checkpoint inhibitors in locally advanced and meta-
static urothelial carcinoma. IMvigor210 tested treat-
ment with atezolizumab in two cohorts: cisplatin-
ineligible patients with locally advanced or metastatic
disease (cohort 1) and cisplatin-pre-treated patients
with locally advanced or metastatic disease (cohort 2)
[61–63]. Cohort 1 enrolled patients with metastatic dis-
ease who were chemotherapy-naïve and cisplatin ineli-
gible. The overall response rate (ORR) in this cohort
was 23% (27/119), and responses occurred in all
subgroups regardless of PD-L1 expression. At the time
of reporting, the median duration of response was not
reached. Median survival was 15.9 months among all
patients [61]. Cohort 2 enrolled patients who had
received at least one prior line of platinum chemother-
apy; 41% had received at least two. The objective re-
sponse proportion in cohort 2 was 15% and was greater
(26%) in patients with high expression of PD-L1 on im-
mune cells (IC2/3) [62, 63]. Overall, 84% of responses
were ongoing at a median of 11.7 months, and the me-
dian duration of response had not been reached. The
median progression-free survival was short in all sub-
groups (2.1 months). However, the median overall sur-
vival was 11.4 months in the high PD-L1 group (IC2/3),
and 7.9 months in the overall cohort [62, 63]. Based on
these results, the FDA granted atezolizumab acceler-
ated approval for use in patients with locally advanced
or metastatic urothelial carcinoma who have disease
progression during or following treatment with
platinum-based chemotherapy for metastatic disease, or
who have disease progression within 1 year of neoadju-
vant or adjuvant treatment with platinum-containing
chemotherapy. Based on data from cohort 1 of the
Fig. 2 Sample template to provide to patients to record BCG treatment/cystoscopy dates
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IMvigor210 trial, atezolizumab was subsequently
granted accelerated approval for frontline treatment of
patients with locally advanced or metastatic urothelial
carcinoma who are ineligible for cisplatin chemother-
apy [64]. For all approvals granted under the acceler-
ated approval pathway based on response rate and
duration of response, continued approval may be con-
tingent on evidence of clinical benefit in further trials.
Phase I/II data from the CheckMate 032 study have also
been reported for nivolumab, a PD-1 inhibitor. In this
study, 78 patients who previously received platinum-based
chemotherapy were treated with single agent nivolumab.
Objective responses were observed in 24.4% of patients
and median overall survival in this study was 9.7 months
[65]. Checkmate 275, a single arm phase II study of nivo-
lumab as a single agent, enrolled 270 patients with locally
advanced or metastatic urothelial carcinoma who had pro-
gressed following platinum-based chemotherapy [66]. Ob-
jective responses were observed in 19.6% of patients.
Higher levels of PD-L1 expression on tumor cells were as-
sociated with higher objective response rates (28.4% with
PD-L1 expression >5%; 23.8% with PD-L1 expression
≥1%; and 16.1% with PD-L1 expression <1%). Based on
these results, the FDA granted nivolumab accelerated ap-
proval for use in patients with locally advanced or meta-
static urothelial carcinoma who have disease progression
during or following treatment with platinum-based
chemotherapy for metastatic disease, or who have disease
progression within 1 year of neoadjuvant or adjuvant
treatment with platinum-containing chemotherapy.
Durvalumab, a PD-L1 inhibitor, was tested in 61 patients
with previously treated metastatic urothelial carcinoma
[67]. In this study, the first 20 patients were enrolled
regardless of PD-L1 status; however, the remainder were re-
quired to have ≥5% of tumor cells expressing PD-L1. In 42
evaluable patients, the objective response rate was 31%; in
patients whose tumors stained positive for PD-L1 (≥25% of
tumor or tumor-infiltrating immune cells), the objective re-
sponse rate was 46% compared with 0% in patients whose
tumors were PD-L1 negative. As a result of these, and more
recent data, durvalumab received accelerated FDA approval
in May 2017 for the treatment of patients with locally ad-
vanced or metastatic urothelial carcinoma who have disease
progression during or after platinum-containing chemo-
therapy, or within 12 months of neoadjuvant or adjuvant
treatment with platinum-containing chemotherapy.
(See Additional file 1 for comments and as yet unpub-
lished data on durvalumab).
A second PD-L1 inhibitor, avelumab, was evaluated in
patients with locally advanced or metastatic urothelial car-
cinoma that failed to respond to platinum-based therapy, as
part of the JAVELIN Solid Tumor Trial (NCT01772004).
Based on data available at the time [confirmed ORR = 13.3%
and 16.1% at minimum follow-up of 13 weeks (n = 226)
and 6 months (n = 161), respectively; median duration of
response not reached in either group; no difference in re-
sponse ate based on PD-L1 tumor expression in the 84% of
patients who were evaluable] avelumab received accelerated
approval for patients with locally advanced or metastatic
urothelial carcinoma whose disease progressed during or
following platinum-containing chemotherapy, or within
12 months of neoadjuvant or adjuvant platinum-
containing chemotherapy [68]. Subsequently published
clinical data have confirmed the efficacy of avelumab in
this indication [69].
Data were also recently presented from the Keynote-045
phase III study of pembrolizumab, an anti-PD-1 antibody,
vs. investigator’s choice of chemotherapy (paclitaxel, doce-
taxel, or vinflunine) [70, 71]. The study was stopped early
based on a pre-specified interim analysis in which pem-
brolizumab demonstrated a significant improvement in
overall survival (median 10.3 vs. 7.4, HR: .73, p = .0022).
The Keynote-045 full report shows pembrolizumab to be
the first therapy to demonstrate a significant survival
advantage over chemotherapy [71]; as of June 2017, pem-
brolizumab remains the only agent showing such an ad-
vantage in a phase III trial. Moreover, the open-label,
phase II Keynote-052 study demonstrated an objective re-
sponse rate of 24% in 100 treatment-naïve, cisplatin ineli-
gible patients treated with pembrolizumab [72]. Based on
these two trials, pembrolizumab was granted two separate
approvals in urothelial cancer: regular approval as second
line therapy for patients whose disease has progressed with
platinum-containing chemotherapy, or within 12 months
of neoadjuvant or adjuvant treatment with platinum-
containing chemotherapy, and accelerated approval as
frontline therapy in cisplatin-ineligible patients [73].
In the first approval of its kind, the FDA recently granted
accelerated approval for use of pembrolizumab in solid tu-
mors demonstrated to be microsatellite instability-high
(MSI-H) or mismatch repair-deficient (dMMR), in patients
with disease progression after prior treatment and who
have no satisfactory alternative treatment options. This is
the first FDA approval based on the presence of a tumor
biomarker as opposed to tumor site and, as such, broadens
treatment options for a subset of patients with a variety of
malignancies, including urothelial carcinoma. The approval
was based on data from 149 patients enrolled in five uncon-
trolled, single-arm clinical trials across 15 cancer types, of
whom 39.6% achieved complete or partial response. Within
this responder group, 78% of patients had response lasting
≥6 months [73].
In the non-randomized CheckMate 032 study, prelimin-
ary data have also been reported on the combination of
nivolumab plus ipilimumab in metastatic urothelial car-
cinoma. At time of presentation the nivolumab (1 mg)
combined with ipilimumab (3 mg) group had an overall
response rate of 38.5%, while the nivolumab (3 mg)
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combined with ipilimumab (1 mg) and nivolumab mono-
therapy groups had overall response rates of 26% and
25.5%, respectively [70]. Overall, these results indicate that
targeting the immune system shows significant promise
for the treatment of metastatic urothelial carcinoma.
Consensus recommendations Atezolizumab, durvalu-
mab, avelumab, pembrolizumab and nivolumab are all
currently FDA-approved and recommended for treat-
ment of patients with locally advanced or metastatic
urothelial carcinoma previously treated with platinum-
based chemotherapy or relapsed within 12 months of
perioperative platinum-based chemotherapy. Pembro-
lizumab demonstrated improved survival and is the
only agent with Level A evidence at this time. There
are currently no evident reasons to select one agent
over the others, other than the practical matters of
dosing and convenience. Atezolizumab and pembroli-
zumab are also recommended as first-line theraphy in
cisplastin-ineligible patients (Fig. 3). Finally, pembroli-
zumab is an appropriate choice of treatment in any
patient whose tumor has the MSI-H biomarker and
whose disease has progressed following prior
treatment, with no satisfactory alternative treatment
options.
Should PD-L1 staining be used routinely in clinical practice?
PD-L1 staining using the Ventana SP142 assay (atezoli-
zumab) or SP263 assay (durvalumab) appears to iden-
tify a patient population more likely to respond to anti-
PD-L1 therapy in the chemotherapy-refractory setting.
However, in both cases durable responses were observed
in patients even with low levels of PD-L1 expression, al-
beit at lower frequencies. PD-L1 has been shown to be a
potentially dynamic biomarker, and the relevance of arch-
ival tumor to the current immune status of the tumor is
unclear. Other PD-L1 assays are available, but none have
been validated as a diagnostic in urothelial carcinoma.7
Consensus recommendations Currently, the data do
not support using PD-L1 immunohistochemistry to se-
lect patients for treatment. However, the FDA has ap-
proved complementary assays for evaluating PD-L1
expression when considering treatment with atezolizu-
mab (Ventana PD-L1 SP142) and durvalumab (Ventana
Fig. 3 All of the treatment options shown may be appropriate. The selection of therapy should be individualized based on patient eligibility and
the availability of therapy, at the discretion of the treating physician. These algorithms represent the consensus recommendations of the Task
Force. (1) Atezolizumab and pembrolizumab are FDA approved for patients with metastatic urothelial carcinoma who are ineligible to receive
cisplatin. (2) Atezolizumab, nivolumab, durvalumab, avelumab, and pembrolizumab are FDA approved for advanced disease that has worsened on
platinum containing regimens or within 12 months of receiving a platinum-containing regimen before (neoadjuvant) or after surgery (adjuvant).
Abbreviations: dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DDMVAC)
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PD-L1 SP263) in urothelial carcinoma. This will lead to
ongoing evaluation of this aspect of patient selection.
Future directions
Ongoing development of novel and/or systemic
immunotherapy in NMIBC, muscle-invasive bladder cancer,
and metastatic bladder cancer
What criteria should be considered for the development of
systemic immunotherapies for treatment of NMIBC?
The development of systemic immunotherapies for treat-
ment of NMIBC should be considered if they offer a
mechanistic advantage or pharmacokinetic advantage to
intravesical therapy. Furthermore, such administration
could be considered for practical reasons if intravesical
therapy of the experimental agent is not deemed feasible.
Clinical investigation of systemic treatments for NMIBC
should be based on the following considerations:
 Mechanism of action of the intervention
 Feasibility of clinical investigation
 Potential systemic toxicities in the context of the
natural/treated history of the underlying disease
state
 Pharmacology demonstrating adequate bladder
exposure when administered systemically, or the
drug doesn’t require direct contact with tumor cells.
High risk NMIBC is particularly well-suited for clinical
investigation based on these considerations. Appropriate
clinical trial design in NMIBC is essential to provide the
most clinically relevant data for each specific disease-risk
category of interest. Recently, the IBCG developed formal
recommendations regarding key definitions, end points,
and overall clinical trial design for NMIBC to encourage
uniformity and promote the development of new agents in
this disease setting [24]. Highlights from these recommen-
dations include the need to develop eligibility criteria and
evaluations on the disease risk category as well as to prop-
erly record the type of failure for BCG (unresponsive, re-
fractory, relapsed, or intolerant). In general, the IBCG
recommends using time-to-recurrence or recurrence-free
survival as a primary end point, while time to progression,
toxicity, disease-specific survival, and overall survival as sec-
ondary end points [24]. A list of selected ongoing immu-
notheraphy trials in bladder cancer is provided in Table 1.
Recommendations for future development The Task
Force discussed several issues and areas of further investiga-
tion that should be addressed in future recommendations:
1. Clinical trials of novel immunotherapy in both
muscle-invasive and metastatic bladder cancer should
explore the potential role for integral biomarkers for
the selection of patients most likely to benefit.
2. Clinical trials of novel immunotherapy in both
muscle-invasive and metastatic bladder cancer
should explore the potential role for a genetic basis
for response including exome analysis and intrinsic
bladder cancer subtypes.
3. T cell infiltration is an important prognostic finding
in urothelial cancer, but this measurement may be
confounded by dynamic changes (i.e., interaction
with therapy). This requires further evaluation and
validation before a recommendation can be made.
4. Selection of patients for clinical trials of systemic
immune therapies based on tissue expression of a
single immune biomarker with measurement via
immunohistochemistry is currently not justified in the
post-platinum population. However, investigation of
chemotherapy-sparing regimens in the first line setting
remains an important area of research.
5. Biomarker development for immunotherapy agents
may require integration of multiple biologic
components as opposed to a single marker.
6. Immune checkpoint inhibitor strategies should be
investigated across disease states of urothelial
carcinoma, though toxicity may limit use in certain
disease states. Combination approaches using
immune checkpoint blockade are also warranted.
7. A formal study of patient navigation tools in patients
with early and locally advanced disease is warranted.
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